Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 10Other solid neoplasm 8Thoracic 5Head & Neck 2Dermatologic 2Lymphoid 1Genitourinary 1

Conditions

Recurrence 1Lymphoma, Non-Hodgkin 1

Interventions

Cyclophosphamide 95Rituximab 81Specimen Handling 78Magnetic Resonance Spectroscopy 65Biopsy 62Vincristine 50Prednisone 50Doxorubicin 50venetoclax 39obinutuzumab 36fludarabine 35Lenalidomide 30ibrutinib 29Dexamethasone 28Cytarabine 28Methotrexate 27prednylidene 24Etoposide 24deltacortene 23CT-P10 23zanubrutinib 22blinatumomab 22acalabrutinib 22fludarabine phosphate 21Nivolumab 21merphos 19Bendamustine Hydrochloride 17pembrolizumab 16Mercaptopurine 16Calcium Dobesilate 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
tislelizumab × Lymphoid × 30 days × Clear all
NCT04539444 2026-06-02

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

The First Affiliated Hospital of Soochow University

Phase 2 Completed
18 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡